Date:7/18/2012

ld," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law. Champions Oncology, Inc.(Dollars in thousands except per share amounts)Reconciliation of GAAP to Non-GAAP Net LossYear Ended April 30 20122011Net loss – GAAP

($8,661)

($3,802)Less: Stock-based compensation

3,323

3,133Net loss - non-GAAP

($5,338)

($669) Reconciliation of GAAP to Non-GAAP Earnings Per Share (EPS)Year Ended April 30 20122011EPS – GAAP

($0.19)

($0.11)Less: Effect of stock-based compensation on EPS

0.08

0.09EPS - non-GAAP

($0.11)

($0.02) Condensed Consolidated Income Statements (Unaudited)Year Ended April 30 20122011% ChangePOS operating revenue

$2,332

$3,382

-31%TOS operating revenue

4,817

3,500

38%  Total operating revenue$7,149$6,8824%Cost of POS

2,356

1,665

42%Cost of TOS

2,543

1,846

'/>"/>

SOURCE Champions Oncology, Inc. Copyright©2012 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
9. GeneLink Reports First Quarter 2012 Financial Results
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Vermillion Reports First Quarter 2012 Results